Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources. In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others. In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”. In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential. In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.
Location: China, Shanghai
Employees: 11-50
Total raised: $15M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | China Grow... | en.cgcvc.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.05.2022 | Series B | $15M | - |
Mentions in press and media 15
| Date | Title | Description |
| 01.06.2025 | InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025 | NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05... |
| 21.11.2024 | InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation | NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Adminis... |
| 08.11.2024 | InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC | NANJING, China, Nov. 8, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC ... |
| 18.10.2022 | InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022 | NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the cli... |
| 18.10.2022 | InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022 | NANJING, China, Oct. 18, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the cli... |
| 30.05.2022 | InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer | NANJING, China, May 29, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleas... |
| 09.05.2022 | InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers | NANJING, China, May 9, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today ann... |
| 09.05.2022 | InxMed Raised $15M in Series B+ Financing | InxMed, a Nanjing, China-based clinical-stage biotechnology company, raised $15M in Series B+ funding. The round was led by Hyfinity Investments. The company intends to use the funds to accelerate ongoing clinical trials of IN10018 for mult... |
| 09.05.2022 | Myovant's Myfembree sNDA gets new PDUFA after CRL speculation; InxMed bags more funds for pivotal studies | Last month, analysts speculated the sNDA for Myovant Sciences and Pfizer’s Myfembree could be hit by a CRL after the FDA identified “deficiencies.” Now, the companies are saying the drug decision data has been pushed b... |
| 14.04.2022 | InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer | NANJING, China, April 14, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN10018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration.... |
Show more